Roche To Take Over Genentech For $47 Billion

GENEVA -- Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn't already own, ending a long corporate struggle with its U.S.-based cancer drug partner.

Topics:  geneva    swiss   roche   genentech    u.s    billion   
BING NEWS:
  • Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors From Regor
    Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...
    09/29/2024 - 6:58 pm | View Link
  • Genentech’s cancer pivot, Pfizer’s sickle cell withdrawal, and a new schizophrenia drug
    On STAT's Readout LOUD podcast, Jonathan Wosen talks about Genentech shutting down its cancer immunology team, and the ambitions of Chinese biotech Akeso.
    09/26/2024 - 8:28 am | View Link
  • Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win
    Up to one-third of patients (currently some 1.7 million worldwide) will develop end-stage kidney disease within ten years, with dialysis and kidney transplants serving as their only available ...
    09/26/2024 - 12:30 am | View Link
  • Roche, Biogen kidney disease drug hits main goal in late-stage study
    Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit Genentech announced Thursday that Gazyva, a lymphoma therapy it co-develops with Biogen (NASDAQ:BIIB), reached the primary endpoint in a Phase 3 trial for ...
    09/25/2024 - 11:48 pm | View Link
  • Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
    The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus ...
    09/25/2024 - 7:34 pm | View Link
  • More
BING SEARCH:
  • Genentech: Press Releases | Monday, Apr 24, 2023
    Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health journeys of patients with neurologic diseases
    09/28/2024 - 6:30 pm | View Website
  • Visit Us
    Following our March 2009 merger with Roche, Genentech's South San Francisco campus became the headquarters for Roche pharmaceutical operations in the United States. All of Genentech's U.S. sites are united by our goal of meeting the needs of patients.
    09/28/2024 - 6:20 am | View Website
  • Genentech
    Explore how we are applying computation & data science to deliver breakthrough medicines to patients. We're committed to developing an inclusive culture where diversity of thought, style, culture, skill sets and perspective is valued and celebrated.
    09/27/2024 - 11:25 pm | View Website
  • Our Medicines & Products
    Our Medicines & Products. Find important safety information and patient resources for all of our currently marketed medicines.
    09/27/2024 - 9:01 pm | View Website
  • Corporate Giving
    Genentech typically only funds programs, projects, and events that are US-based. Learn more about funding through our parent company, Roche, for projects outside of the U.S.
    09/27/2024 - 5:19 pm | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News